Rohira AD, Chen CY, Allen JR, Johnson DL (2013) Covalent Small Ubiquitin-like Modifier (SUMO) Modification of Maf1 Protein Controls RNA Polymerase III-dependent Transcription Repression. J Biol Chem 288, 19288-95 23673667

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K35-sm - MAF1 (human) ▲

Modsite: RIESYSCkMAGDDKH SwissProt Entrez-Gene Orthologous residues MAF1 (human): K35‑sm, MAF1 (mouse): K35‑sm, MAF1 (rat): K35‑sm Characterization Methods used to characterize site in vivo:  mutation of modification site, western blotting Disease tissue studied:  brain cancer, glioblastoma, glioma Relevant cell lines - cell types - tissues:  COS7 (fibroblast), HEK293T (epithelial), U87MG (glial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE UBC9 (human) siRNA inhibition of enzyme DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  cell growth, inhibited, transcription, inhibited Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays POLR3A (human) Induces co-immunoprecipitation